Oncotype DX Breast Recurrence Score

Determining Your Patient's Eligibility

The Oncotype DX Breast Recurrence Score provides comprehensive and actionable direction across the spectrum of ER-positive, invasive breast cancer biology, predicting the likelihood of adjuvant therapy benefit as well as your patient’s 10-year risk of distant recurrence. This information will help to guide your recommendation to personalize treatment for each of your patients.

The Breast Recurrence Score is intended for use in all newly diagnosed patients with invasive breast cancer who are:

  • Node-negative or node-positive (1-3)
  • ER-positive
  • HER2-negative
Which patients may benefit from the Oncotype DX Breast Recurrence Score test? NICE Diagnostic Guidance* on the use of the Oncotype DX Breast Recurrence Score test for NHS patients
ER: Oestrogen Receptor HER2: Human Epidermal growth factor Receptor 2 *Updated NICE Guidance DG34 (including micrometastatic disease; see section 5.4 of guidance)
Update NICE Breast Cancer Quality Standard [QS12] recommends Oncotype DX testing. (June 2016, www.nice.org.uk/Guidance/QS12)
  1. npj Breast Cancer volume 3, Article number: 33 (2017)
  2. Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx385.008, https://doi.org/10.1093/annonc/mdx385.008
  3. npj Breast Cancer volume 3, Article number: 32 (2017)

*NCCN and NCCN Guidelines are registered trademarks of the National Comprehensive Cancer Network. *ASCO is a registered trademark of the American Society of Clinical Oncology. NCCN and ASCO do not endorse any product or therapy.

This webpage is intended to be viewed by UK Healthcare Professionals only and not by members of the public. If you are not a healthcare professional, click here for more information

For Patients

Clinical Validation:

Clalit Health Services' registry analysis complements findings from TAILORx, SEER, and WSG.

Read Full Text

Clinical Validation:
ESMO 2017b

Breast cancer-specific survival in young women <40 years with node negative luminal breast cancer

Read Poster Abstract

Clinical Validation:

The Clalit Health Services team describes evidence in 709 node-positive patients supporting the use of endocrine therapy alone.

Read Full Text

Contact Us

Get in Touch
Making cancer care smarter.™

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.